Gérard Wagemaker

Prof. Gérard Wagemaker


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
NTNiek P. van Til
Niek P. van Til
RSRoya Sarwari
Roya Sarwari
TVTrudi P. Visser
Trudi P. Visser
JHJulia Hauer
Julia Hauer
CLChantal Lagresle-Peyrou
Chantal Lagresle-Peyrou
GWGérard Wagemaker
Gérard Wagemaker

1 January 2012 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
EWEvert-Jan Wils
Evert-Jan Wils
Fatima Aerts-KayaFatima Aerts-Kaya
Fatima Aerts-Kaya
ERElwin J.C. Rombouts
Elwin J.C. Rombouts
IMIrene van Mourik
Irene van Mourik
ARAnita Rijken-Schelen
Anita Rijken-Schelen
JCJan J. Cornelissen
Jan J. Cornelissen

28 June 2014
Verified
Book Chapter
Closed access
PDF file
NTNiek P. van Til
Niek P. van Til
GWGérard Wagemaker
Gérard Wagemaker

1 October 2014 in Human Gene Therapy
Verified
Journal Article
Closed access
GWGérard Wagemaker
Gérard Wagemaker
After more than 20 years of development, lentiviral hematopoietic stem cell gene therapy has entered the stage of initial clinical implementation for immune deficiencies and storage disorders. This brief review summarizes the development and applications, focusing on the lysosomal enzyme deficiencies, especially Pompe disease.

1 October 2014 in Human Gene Therapy
Verified
Journal Article
Closed access
MHMarshall W. Huston
Marshall W. Huston
ARAdriaan R.A. Riegman
Adriaan R.A. Riegman
RYRana Yadak
Rana Yadak
YHYvette van Helsdingen
Yvette van Helsdingen
HBHelen de Boer
Helen de Boer
GWGérard Wagemaker
Gérard Wagemaker
Hematopoietic stem cell (HSC) gene therapy is a demonstrated effective treatment for X-linked severe combined immunodeficiency (SCID-X1), but B-cell reconstitution and function has been deficient in many of the gene therapy treated patients. Cytoreductive preconditioning is known to improve HSC engraftment, but in general it is not considered for SCID-X1 since the poor health of most of these patients at diagnosis and the risk of toxicity preclude the conditioning used in standard bone marrow stem cell transplantation. We hypothesized that mobilization of HSC by granulocyte colony-stimulating factor (G-CSF) should create temporary space in bone marrow niches to improve engraftment and thereby B-cell reconstitution. In the present pilot study supplementing our earlier preclinical evaluation (Huston et al., 2011), Il2rg(-/-) mice pretreated with G-CSF were transplanted with wild-type lineage negative (Lin(-)) cells or Il2rg(-/-) Lin(-) cells transduced with therapeutic IL2RG lentiviral vectors. Mice were monitored for reconstitution of lymphocyte populations, level of donor cell chimerism, and antibody responses as compared to 2 Gy total body irradiation (TBI), previously found effective in promoting B-cell reconstitution. The results demonstrate that G-CSF promotes B-cell reconstitution similar to low-dose TBI and provides proof of principle for an alternative approach to improve efficacy of gene therapy in SCID patients without adverse effects associated with cytoreductive conditioning.

1 January 2015 in Journal of Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
QLQiushi Liang
Qiushi Liang
MSMerel Stok
Merel Stok
YHYvette van Helsdingen
Yvette van Helsdingen
GVGuus van der Velden
Guus van der Velden
EJEd Jacobs
Ed Jacobs
GWGérard Wagemaker
Gérard Wagemaker